HUP9902796A2 - Use of cytokine production inhibitors for producing medicines, methods for their identification and novel imidazole derivatives - Google Patents
Use of cytokine production inhibitors for producing medicines, methods for their identification and novel imidazole derivativesInfo
- Publication number
- HUP9902796A2 HUP9902796A2 HU9902796A HUP9902796A HUP9902796A2 HU P9902796 A2 HUP9902796 A2 HU P9902796A2 HU 9902796 A HU9902796 A HU 9902796A HU P9902796 A HUP9902796 A HU P9902796A HU P9902796 A2 HUP9902796 A2 HU P9902796A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- arginine
- modified
- identification
- methods
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000016396 cytokine production Effects 0.000 title 1
- 150000002460 imidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000004475 Arginine Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010054805 Macroangiopathy Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 206010002022 amyloidosis Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 abstract 1
- 239000004062 cytokinin Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 239000004575 stone Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány őlyan vegyületekkel vagy ligandűmők alkalmazásáravőnatkőzik, amelyek gátőlják az a-őxő-aldehiddel módősítőtt arginingyökök kötését, ide tartőznak az őlyan új, (I) általánős képletűvegyületek, ahől a képletben R1 jelentése adőtt esetben helyettesítettaril-, aralkil- vagy alkilcsőpőrt, R2 jelentése hidrőgénatőm, R3 és R4jelentése egymástól függetlenül hidrőgénatőm vagy aril- vagyalkilcsőpőrt, a vegyültek közé értendők ezek sói, észterei vagyhidratált főrmái is. Az ilyen vegyültek valamely gyógyászatihőrdőzóval együtt kiszerelhetők, és alkalmazhatók diabetes mellitűssalés makrővaszkűláris betegséggel társűló krónikűs klinikai kőmplikációkés Alzheimer-kórral társűló amilőidózis kezelésére vagy megelőzésére.A találmány tárgyát képezi még a-őxő-aldehiddel módősítőtt arginingyökre agőnista vegyületek alkalmazása citőkinnel kapcsőlatősbetegségek kezelésére vagy megelőzésére alkalmas gyógyszerekelőállítására. A találmány szerinti bizőnyős a-őxő-aldehiddelmódősítőtt arginingyökök is le vannak írva, amelyek alkalmasakterápiás aktivitású vegyületek átvizsgálási eljárásaihőz. (I) ŕThe invention relates to the use of such compounds or ligands that inhibit the binding of arginine radicals modified with α-oxoaldehyde, this includes the very new compounds of general formula (I), in which R1 in the formula is optionally replaced by tertaryl, aralkyl or alkyl, and R2 is a hydrogen atom , R3 and R4 independently mean a hydrogen atom or an aryl or alkyl group, the compounds include their salts, esters or hydrated derivatives. Such compounds can be prepared together with a medical anti-inflammatory and can be used for the treatment or prevention of chronic clinical stone complications associated with diabetes mellitus macrovascular disease and amyloidosis associated with Alzheimer's disease. The subject of the invention is also the use of oxoaldehyde-modified arginine radical agonist compounds for the production of medicines suitable for the treatment or prevention of cytokinin diseases. Arginine radicals modified with α-oxyaldehyde according to the invention are also described, which are suitable for screening procedures for compounds with therapeutic activity. (I) ŕ
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9611046.5A GB9611046D0 (en) | 1996-05-25 | 1996-05-25 | Pharmacological compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9902796A2 true HUP9902796A2 (en) | 2000-04-28 |
| HUP9902796A3 HUP9902796A3 (en) | 2000-07-28 |
Family
ID=10794362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9902796A HUP9902796A3 (en) | 1996-05-25 | 1997-05-23 | Use of cytokine production inhibitors for producing medicines, methods for their identification and novel imidazole derivatives |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0859762A1 (en) |
| JP (1) | JPH11510521A (en) |
| AU (1) | AU2910397A (en) |
| BR (1) | BR9702238A (en) |
| CA (1) | CA2227811A1 (en) |
| GB (1) | GB9611046D0 (en) |
| HU (1) | HUP9902796A3 (en) |
| IL (1) | IL123033A0 (en) |
| NO (1) | NO980299L (en) |
| WO (1) | WO1997045417A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| JP2008503460A (en) | 2004-06-16 | 2008-02-07 | ワイス | Diphenylimidazopyrimidine and imidazolamine as inhibitors of β-secretase |
| RU2006142552A (en) | 2004-06-16 | 2008-07-27 | Вайет (Us) | AMINO-5,5-DIPHENYLIMIDAZOLONE DERIVATIVES AS B-SECRETASE INHIBITORS |
| CN101103034A (en) | 2005-01-14 | 2008-01-09 | 惠氏公司 | Amino-imidazolones for the inhibition of beta-secretase |
| RU2007124935A (en) | 2005-02-01 | 2009-03-10 | Вайет (Us) | AMINOPYRIDINES AS β-SECTRETASIS INHIBITORS |
| RU2007131043A (en) | 2005-02-14 | 2009-03-20 | Вайет (Us) | AZOLILACYLGUANIDINES USED AS BETA-SECRETASE INHIBITORS |
| TW200738683A (en) | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| BRPI0616757A2 (en) | 2005-09-26 | 2011-06-28 | Wyeth Corp | compound of formula i; process for treating a disease or disorder associated with excessive bace activity; process for modulating bace activity; process for treating alzheimer's disease; and pharmaceutical composition |
| WO2007100536A1 (en) | 2006-02-24 | 2007-09-07 | Wyeth | DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE |
| US7700606B2 (en) | 2006-08-17 | 2010-04-20 | Wyeth Llc | Imidazole amines as inhibitors of β-secretase |
| MX2009006228A (en) | 2006-12-12 | 2009-06-22 | Schering Corp | Aspartyl protease inhibitors. |
| CL2008000791A1 (en) | 2007-03-23 | 2008-05-30 | Wyeth Corp | COMPOUNDS DERIVED FROM 2-AMINO-5- (4-DIFLUOROMETOXI-FENIL) -5-FENIL-IMIDAZOLIDIN-4-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH EXCESSIVE BACE ACTIVITY, SUCH AS ILLNESS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4005205A (en) * | 1974-04-24 | 1977-01-25 | Smith Kline & French Laboratories Limited | Compositions and methods for inhibiting H2 histamine receptors |
| EP0102026A3 (en) * | 1982-08-20 | 1984-05-16 | Hoechst Uk Limited | Thiazole derivatives |
| PL140069B1 (en) * | 1982-12-21 | 1987-03-31 | Pfizer | Method of obtaining new derivatives of dihydropiridine |
| GB8311443D0 (en) * | 1983-04-27 | 1983-06-02 | Smith Kline French Lab | Chemical compounds |
| AU5428686A (en) * | 1985-03-12 | 1986-09-18 | Smith Kline & French Laboratories Limited | Imidazolinone and thiazolinone derivatives |
| FI902321A0 (en) * | 1989-05-19 | 1990-05-09 | Eisai Co Ltd | BUTENSYRADERIVAT. |
| GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
-
1996
- 1996-05-25 GB GBGB9611046.5A patent/GB9611046D0/en active Pending
-
1997
- 1997-05-23 WO PCT/GB1997/001415 patent/WO1997045417A1/en not_active Application Discontinuation
- 1997-05-23 BR BR9702238A patent/BR9702238A/en not_active Application Discontinuation
- 1997-05-23 IL IL12303397A patent/IL123033A0/en unknown
- 1997-05-23 EP EP97923245A patent/EP0859762A1/en not_active Withdrawn
- 1997-05-23 HU HU9902796A patent/HUP9902796A3/en unknown
- 1997-05-23 JP JP9541830A patent/JPH11510521A/en active Pending
- 1997-05-23 CA CA002227811A patent/CA2227811A1/en not_active Abandoned
- 1997-05-23 AU AU29103/97A patent/AU2910397A/en not_active Abandoned
-
1998
- 1998-01-23 NO NO980299A patent/NO980299L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP9902796A3 (en) | 2000-07-28 |
| WO1997045417A1 (en) | 1997-12-04 |
| AU2910397A (en) | 1998-01-05 |
| MX9800670A (en) | 1998-09-30 |
| IL123033A0 (en) | 1998-09-24 |
| JPH11510521A (en) | 1999-09-14 |
| BR9702238A (en) | 1999-07-27 |
| EP0859762A1 (en) | 1998-08-26 |
| NO980299L (en) | 1998-03-24 |
| NO980299D0 (en) | 1998-01-23 |
| CA2227811A1 (en) | 1997-12-04 |
| GB9611046D0 (en) | 1996-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9902796A2 (en) | Use of cytokine production inhibitors for producing medicines, methods for their identification and novel imidazole derivatives | |
| HUP0102295A2 (en) | Benzamide derivatives for the treatment of diseases mediated by cytokines | |
| SE0104334D0 (en) | Therapeutic agents | |
| ATE268179T1 (en) | USE OF SUBSTITUTED IMIDAZO (1,2-A)PYRIDINE, PYRIMIDINE AND PYRAZINE-3-YL-AMINE DERIVATIVES FOR THE PRODUCTION OF NOS INHIBITION MEDICATIONS | |
| DE69531213D1 (en) | NEW HETEROCYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND MEDICAL USE | |
| HUP0401241A2 (en) | Novel cyclohexyl sulphones, process for their preparation and pharmaceutical compositions containing them | |
| HUP0401849A2 (en) | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | |
| AU2002359164A8 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
| NO923197D0 (en) | SUBSTITUTED HETEROCYCLIC COMPOUNDS | |
| DK0975595T3 (en) | cocaine analogs | |
| ATE193827T1 (en) | USE OF 1-2-4-BENZOTRIAZINE OXIDES IN THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF TUMORS | |
| PT88526A (en) | L-DOPA DERIVATIVES OR THEIR ACID ADDITION SALTS PROCESS FOR PRODUCING SAME AND THEIR USE | |
| DE60221283D1 (en) | USE OF OXINDOLE DERIVATIVES FOR TREATING DISEASES RELATED TO DEMENTIA, ALZHEIMER'S DISEASE AND AIDS ASSOCIATED WITH GLYCOGENSYNTHASEKINASE-3 | |
| IT1317048B1 (en) | USE OF PAMOIC ACID OR ITS DERIVATIVE, OR ANALOGUE, FOR THE PREPARATION OF A MEDICATION FOR THE TREATMENT OF DISEASES | |
| ATE159029T1 (en) | PHOSPHONIC ACID DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF | |
| ATE85334T1 (en) | BISPHENYLALKYLPIPERAZINE DERIVATIVES, METHOD OF MANUFACTURE AND DRUG PREPARATION. | |
| RU99103681A (en) | AMIDES OF ALPHA-AMINO ACIDS, THEIR PRODUCTION AND THERAPEUTIC USE | |
| ATE105302T1 (en) | FLUORAMIDE DERIVATIVES WITH INHIBITING ACTIVITY AGAINST HUMAN LEUKOCYTE ELASTASIS. | |
| ATE236634T1 (en) | USE OF 4-PIPERIDINE METHANOL DERIVATIVES FOR THE TREATMENT OF NEURAL DEVELOPMENTAL DISORDERS | |
| ATE181503T1 (en) | USE OF IDAZOXAN AND DERIVATIVES FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF PARKINSONISM AND ITS EVOLUTION | |
| DE69200840T2 (en) | Urea and thiourea derivatives, manufacture and therapeutic use. | |
| DE69421705T2 (en) | Use of Efaroxan and its derivatives for the manufacture of a medicament for the treatment of neurogenerative diseases | |
| IE780851L (en) | 2-benzylperhydroazepines. | |
| DE69228235T2 (en) | Use of an agent for the manufacture of a medicament for the treatment of liver disease | |
| RO81362B1 (en) | Process for preparing vibramycin chlorohydrate |